At a glance
ClinicalIndex Comparison Record- ✓Male participants
- ✓Aged 18–50 years
- ✓Diagnosed with schizophrenia or schizoaffective disorder
- ✓Clinically stable on current medication for ≥3 months
- ✕Psychoactive substance dependence within past 6 months or substance abuse within past month
- ✕History of head trauma or neurological disorder
- ✕Seizure disorder
- ✕History of myocardial infarction, arrhythmia, or other heart disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist
In Brief
A Phase 2 clinical trial evaluating Merck L-830982 and Placebo for Schizophrenia. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.
Study Details
Timeline
Interventions
The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.